

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8014368

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT
<b>EFFECTIVE DATE:</b>	03/20/2023

**CONVEYING PARTY DATA**

Name	Execution Date
BLACKBERRY CORPORATION	05/11/2023

**RECEIVING PARTY DATA**

<b>Name:</b>	MALIKIE INNOVATIONS LIMITED
<b>Street Address:</b>	THE GLASSHOUSES GH2, 92 GEORGES STREET LOWER DUN LAOGHAIRE
<b>City:</b>	DUBLIN
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	A96 VR66

**PROPERTY NUMBERS Total: 29**

Property Type	Number
Patent Number:	10616940
Patent Number:	10952062
Patent Number:	9518835
Patent Number:	11047701
Patent Number:	8606516
Patent Number:	8908516
Patent Number:	6862500
Patent Number:	6925378
Patent Number:	7076365
Patent Number:	8271190
Patent Number:	8566021
Patent Number:	7957893
Patent Number:	7949491
Patent Number:	8306777
Patent Number:	7516041
Patent Number:	8280395
Patent Number:	8612437
Patent Number:	8112522
Patent Number:	8307090

PATENT

Property Type	Number
Patent Number:	7987260
Patent Number:	9245040
Patent Number:	9310214
Patent Number:	8660794
Patent Number:	8340898
Patent Number:	7801675
Patent Number:	9185678
Patent Number:	8339990
Patent Number:	9173174
Patent Number:	10009643

**CORRESPONDENCE DATA**

**Fax Number:** (703)739-2815

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Email:** iprecordals@clarivate.com, neda.lukovic@clarivate.com

**Correspondent Name:** CPA GLOBAL LIMITED

**Address Line 1:** LIBERATION HOUSE

**Address Line 2:** CASTLE STREET

**Address Line 4:** ST HELIER, JERSEY JE1 1BL

<b>NAME OF SUBMITTER:</b>	HELEN BIRRELL
<b>SIGNATURE:</b>	/IPR/NL/MalikeInnKPIIPR2023035/AG6/29P/
<b>DATE SIGNED:</b>	06/20/2023

**Total Attachments: 6**

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page1.tif

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page2.tif

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page3.tif

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page4.tif

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page5.tif

source=Assignment - BlackBerry Corporation to Malike Innovations Limited Schedule I#page6.tif

## PATENT ASSIGNMENT

WHEREAS, BlackBerry Corporation (“Seller”), a legal entity organized and existing under the laws of the State of Delaware, having its principal place of business at 3001 Bishop Drive, Suite 400, San Ramon, California, 94583 USA, is the owner of the patents and patent applications set forth in Schedule 1 hereto (the “Assigned Patents”);

WHEREAS, Malikie Innovations Limited (“Purchaser”), a legal entity organized and existing under the laws of Ireland having its principal place of business at The Glasshouses GH2, 92 Georges Street Lower, Dun Laoghaire, Dublin, Ireland, A96 VR66, desires to acquire the Seller’s entire right, title and interest in, to and under the Assigned Patents; and

WHEREAS Seller’s parent company, Blackberry Limited and Purchaser are party to that certain Patent Sale Agreement, dated March 20, 2023 (the “PSA”). Capitalized terms used but not defined herein shall have the definitions set forth in the PSA.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, as of May 11, 2023, Seller hereby irrevocably sells, conveys, transfers, assigns and delivers to Purchaser, and Purchaser acquires from Seller, all of Seller’s right, title and interest in and to the following: (i) the Assigned Patents and the inventions and discoveries claimed therein; (ii) all claims, causes of action and enforcement rights of any kind, and all rights to sue for past, present or future infringement of, any of the Assigned Patents and to collect and retain any and all damages, costs, profits, injunctive relief and other remedies for or relating to any such past, present or future infringement of the Assigned Patents; (iii) the right to make, use, sell, offer for sale, import and otherwise fully exploit all inventions and discoveries claimed in any of the Assigned Patents; (iv) except for those arising from or payable pursuant to Encumbrances existing as of the Closing that survive Closing, all rights to collect royalties, license fees or other amounts relating to the Assigned Patents; and (v) all rights to apply for, file, register, maintain, prosecute, extend, renew, enforce, license and otherwise exploit in any or all countries of the world patents, patent applications, certificates of invention, utility models, industrial design protection, design patent protection and other governmental grants or issuances of any kind in respect of any and all of the Assigned Patents and any and all of the inventions, invention disclosures, designs and discoveries described or disclosed therein, in each case of (i) through (v), subject to all Existing Encumbrances and Other Permitted Encumbrances on such rights, other than those that will be released as of the Closing, and excluding the Excluded Patent Rights.

Seller does hereby authorize and request the Commissioner of Patents and Trademarks of the United States of America or equivalent authority or government office elsewhere in the world to issue Letters Patent, as shall be granted based upon its Assigned Patents and applications (including, without limitation, any divisional, continuing, reissue or other application claiming priority therefrom), to the Purchaser, its successors and assigns.

This assignment may be recorded with the United States Patent and Trademark Office and other equivalent authority or government office elsewhere in the world.

This assignment is being provided and entered into subject to all the terms and conditions of the PSA. This assignment shall not in any way limit, change, alter, or restrict any of the terms, covenants, rights and obligations as set forth in the PSA. To the extent that there are

any discrepancies between this assignment and the PSA, the applicable terms and provisions of the PSA shall govern.

This assignment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same agreement. Copies of executed counterparts transmitted by facsimile, email or other electronic transmission shall be considered original executed counterparts; provided, that receipt of copies of such counterparts is confirmed.

*[SIGNATURE PAGE FOLLOWS]*

IN WITNESS WHEREOF, THE PARTIES, BY THEIR DULY AUTHORIZED REPRESENTATIVES, HAVE EXECUTED THIS PATENT ASSIGNMENT.

**MALIKIE INNOVATIONS LIMITED**

By: 

Name: Angela Quintan

Title: Director

Date: May 11, 2023

**BLACKBERRY CORPORATION**

By: \_\_\_\_\_

Name: Steve Rai

Title: Chief Financial Officer

Date: May 11, 2023


[Signature Page to Patent Assignment]

IN WITNESS WHEREOF, THE PARTIES, BY THEIR DULY AUTHORIZED REPRESENTATIVES, HAVE EXECUTED THIS PATENT ASSIGNMENT.

**MALIKIE INNOVATIONS LIMITED**

**BLACKBERRY CORPORATION**

By: \_\_\_\_\_

By:  \_\_\_\_\_

Name: \_\_\_\_\_

Name: Steve Rai

Title: \_\_\_\_\_

Title: Chief Financial Officer

Date: \_\_\_\_\_

Date: May 11, 2023

*[Signature Page to Closing Patent Assignment]*

**SCHEDULE 1**

**Assigned Patents and Applications**

*Provided separately.*

Notwithstanding anything to the contrary in this Agreement, 35596-4-US-PAT (8,873,407) is not included in the definition of Assigned Patents.

BB Family ID	BB Case ID	Filing Num.	Pub. Num.	Granted Num.	Current Status
11072	11072-CA-PCT	2533284		2533284	Granted
11072	11072-CN-PCT	200480029836.9	1867915	200480029836.9	Granted
11072	11072-EP-EPT	04715067.7	1661035		Abandoned
11072	11072-HK-FPR	06112974.9	1091291		Abandoned
11072	11072-IN-PCT	740/DELNP/2006		337193	Granted
11072	11072-SG-PCT	200600798.3	119606	119606	Granted
11072	11072-US-CNT	12/102083	2008/0195667	7739343	Granted
11072	11072-US-CNT[2]	12/814703	2010/0287252	8065377	Granted
11072	11072-US-CNT[3]	13/296265	2012/0059894	8447821	Granted
11072	11072-US-CNT[4]	13/895880	2013/0254860		Abandoned
11072	11072-US-PAT	10/778590	2005/0038859	7373386	Granted
11072	11072-US-PRV	60/494233			Converted
11072	11072-WO-PCT	PCT/US2004/005768	2005/020108		National Phase Entered
30186-1	30186-1-CA-PAT	2550389	2550389	2550389	Granted
30186-1	30186-1-US-PAT	11/165309	2006/0293032	7363026	Granted
36030	36030-US-CNT	14/080356	2014/0142852	9518835	Granted
36030	36030-US-CNT[2]	15/365552	2017/0146357	11047701	Granted
36030	36030-US-PAT	11/290869	2006/0229802	8606516	Granted
36030	36030-US-PRV	60/631642			Converted
36031	36031-CN-PCT	200380101515.0	1705954	200380101515.0	Granted
36031	36031-DE-EPT	03781356.5	1563442	60331671.9	Granted
36031	36031-EP-EPT	03781356.5	1563442	1563442	Validated
36031	36031-FR-EPT	03781356.5	1563442	1563442	Granted
36031	36031-GB-EPT	03781356.5	1563442	1563442	Granted
36031	36031-US-DIV	13/220237	2011/0310733	8908516	Granted
36031	36031-US-PAT	10/272039	2004/0073361		Abandoned
36031	36031-WO-PCT	PCT/US03/033314	2004/036815		National Phase Entered
36034	36034-DE-EPT	04760970.6	1631790	602004041789.0	Granted
36034	36034-EP-EPT	04760970.6	1631790	1631790	Validated
36034	36034-FR-EPT	04760970.6	1631790	1631790	Granted
36034	36034-GB-EPT	04760970.6	1631790	1631790	Granted
36034	36034-NL-EPT	04760970.6	1631790	1631790	Granted
36034	36034-US-PAT	10/437205	2004/0230370	6925378	Granted
36034	36034-WO-PCT	PCT/US04/14583	2004/102986		National Phase Entered
36036	36036-US-CNT	13/094407	2011/0264708	8271190	Granted
36036	36036-US-CNT[2]	13/601502	2013/0060465	8566021	Granted
36036	36036-US-PAT	11/292392	2006/0155464	7957893	Granted
36036	36036-US-PRV	60/632276			Converted
36036	36036-WO-PCT	PCT/US2005/043381	2006/060518		No Further Filings
36037	36037-AU-PCT	2006304589		2006304589	Granted
36037	36037-CA-PCT	2625820		2625820	Granted
36037	36037-DE-EPT	06826206.2	1946044	602006035109.7	Granted
36037	36037-EP-EPT	06826206.2	1946044	1946044	Validated
36037	36037-EP-ETD	13155030.3	2597425		Abandoned
36037	36037-FR-EPT	06826206.2	1946044	1946044	Granted
36037	36037-GB-EPT	06826206.2	1946044	1946044	Granted
36037	36037-NL-EPT	06826206.2	1946044	1946044	Granted
36037	36037-US-CNT	12/384657	2009/0228212	7949491	Granted
36037	36037-US-CNT[2]	13/089201	2011/0196611	8306777	Granted
36037	36037-US-PAT	11/581808	2007/0129892	7516041	Granted
36037	36037-US-PRV	60/726894			Converted
36037	36037-WO-PCT	PCT/US06/40751	2007/047780		National Phase Entered
36042	36042-US-CNT	13/182860	2011/0270982	8112522	Granted
36042	36042-US-CNT[2]	13/361035	2012/0131200	8307090	Granted
36042	36042-US-PAT	11/511765	2008/0052391	7987260	Granted
36049	36049-CA-PCT	2691960		2691960	Granted
36049	36049-DE-EPT	08794487.2	2168111	602008018245.2	Granted
36049	36049-EP-EPT	08794487.2	2168111	2168111	Validated
36049	36049-FR-EPT	08794487.2	2168111	2168111	Granted
36049	36049-GB-EPT	08794487.2	2168111	2168111	Granted
36049	36049-NL-EPT	08794487.2	2168111	2168111	Granted
36049	36049-US-CNT	12/887452	2011/0010091	8340898	Granted
36049	36049-US-PAT	11/827747	2009/0088971	7801675	Granted
36049	36049-WO-PCT	PCT/US08/08618	2009/011839		National Phase Entered
36050	36050-US-CNT	13/706889	2013/0095880	9185678	Granted
36050	36050-US-PAT	11/903442		8339990	Granted